Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation. / Ebbesen, M S; Kissow, H; Hartmann, B; Grell, K; Gørløv, J S; Kielsen, K; Holst, J J; Müller, K.

In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 6, 2019, p. 1085-1091.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Ebbesen, MS, Kissow, H, Hartmann, B, Grell, K, Gørløv, JS, Kielsen, K, Holst, JJ & Müller, K 2019, 'Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation', Biology of Blood and Marrow Transplantation, vol. 25, no. 6, pp. 1085-1091. https://doi.org/10.1016/j.bbmt.2019.01.036

APA

Ebbesen, M. S., Kissow, H., Hartmann, B., Grell, K., Gørløv, J. S., Kielsen, K., ... Müller, K. (2019). Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation, 25(6), 1085-1091. https://doi.org/10.1016/j.bbmt.2019.01.036

Vancouver

Ebbesen MS, Kissow H, Hartmann B, Grell K, Gørløv JS, Kielsen K et al. Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation. 2019;25(6):1085-1091. https://doi.org/10.1016/j.bbmt.2019.01.036

Author

Ebbesen, M S ; Kissow, H ; Hartmann, B ; Grell, K ; Gørløv, J S ; Kielsen, K ; Holst, J J ; Müller, K. / Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation. In: Biology of Blood and Marrow Transplantation. 2019 ; Vol. 25, No. 6. pp. 1085-1091.

Bibtex

@article{53af41fcaa5443ba93bc2ebed123bb4d,
title = "Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation",
abstract = "Autologous stem cell transplantation (ASCT) is challenged by side effects that may be propagated by chemotherapy-induced mucositis resulting in bacterial translocation and systemic inflammation. Since gastrointestinal damage appear as an early event in this cascade of reactions, we hypothesized that markers reflecting damage to the intestinal barrier could serve as early predictive markers of toxicity. Glucagon-like peptide-1 (GLP-1), a well-known regulator of blood glucose, has been found to promote intestinal growth and repair in animal studies. We investigated fasting GLP-1 plasma levels in 66 adults undergoing ASCT for lymphoma and multiple myeloma. GLP-1 increased significantly after chemotherapy reaching peak levels at day +7 post-transplant (median (IQR): 8 (4-12) before conditioning vs. 10 (6-17) pmol/L at day +7, P=0.007). The magnitude of the GLP-1 increase was related to the intensity of conditioning. GLP-1 at the day of transplantation (day 0) was positively associated with peak C-reactive protein (CRP) levels (46 mg/L per GLP-1 doubling, P<0.001) and increase in days with fever (32{\%} per GLP-1 doubling, P=0.0058). Patients with GLP-1 above the median at day 0 had higher CRP levels from day +3 to day +10 post-transplant than patients with lower GLP-1 (P≤0.041) with peak values of 238 vs. 129 mg/L, respectively. This study, which represents the first clinical investigation of fasting GLP-1 in relation to high-dose chemotherapy, provides evidence that GLP-1 plays a role in regulation of mucosal defenses. Fasting GLP-1 levels may serve as an early predictor of systemic inflammation and fever in patients receiving high-dose chemotherapy.",
author = "Ebbesen, {M S} and H Kissow and B Hartmann and K Grell and G{\o}rl{\o}v, {J S} and K Kielsen and Holst, {J J} and K M{\"u}ller",
note = "Copyright {\circledC} 2019. Published by Elsevier Inc.",
year = "2019",
doi = "10.1016/j.bbmt.2019.01.036",
language = "English",
volume = "25",
pages = "1085--1091",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation

AU - Ebbesen, M S

AU - Kissow, H

AU - Hartmann, B

AU - Grell, K

AU - Gørløv, J S

AU - Kielsen, K

AU - Holst, J J

AU - Müller, K

N1 - Copyright © 2019. Published by Elsevier Inc.

PY - 2019

Y1 - 2019

N2 - Autologous stem cell transplantation (ASCT) is challenged by side effects that may be propagated by chemotherapy-induced mucositis resulting in bacterial translocation and systemic inflammation. Since gastrointestinal damage appear as an early event in this cascade of reactions, we hypothesized that markers reflecting damage to the intestinal barrier could serve as early predictive markers of toxicity. Glucagon-like peptide-1 (GLP-1), a well-known regulator of blood glucose, has been found to promote intestinal growth and repair in animal studies. We investigated fasting GLP-1 plasma levels in 66 adults undergoing ASCT for lymphoma and multiple myeloma. GLP-1 increased significantly after chemotherapy reaching peak levels at day +7 post-transplant (median (IQR): 8 (4-12) before conditioning vs. 10 (6-17) pmol/L at day +7, P=0.007). The magnitude of the GLP-1 increase was related to the intensity of conditioning. GLP-1 at the day of transplantation (day 0) was positively associated with peak C-reactive protein (CRP) levels (46 mg/L per GLP-1 doubling, P<0.001) and increase in days with fever (32% per GLP-1 doubling, P=0.0058). Patients with GLP-1 above the median at day 0 had higher CRP levels from day +3 to day +10 post-transplant than patients with lower GLP-1 (P≤0.041) with peak values of 238 vs. 129 mg/L, respectively. This study, which represents the first clinical investigation of fasting GLP-1 in relation to high-dose chemotherapy, provides evidence that GLP-1 plays a role in regulation of mucosal defenses. Fasting GLP-1 levels may serve as an early predictor of systemic inflammation and fever in patients receiving high-dose chemotherapy.

AB - Autologous stem cell transplantation (ASCT) is challenged by side effects that may be propagated by chemotherapy-induced mucositis resulting in bacterial translocation and systemic inflammation. Since gastrointestinal damage appear as an early event in this cascade of reactions, we hypothesized that markers reflecting damage to the intestinal barrier could serve as early predictive markers of toxicity. Glucagon-like peptide-1 (GLP-1), a well-known regulator of blood glucose, has been found to promote intestinal growth and repair in animal studies. We investigated fasting GLP-1 plasma levels in 66 adults undergoing ASCT for lymphoma and multiple myeloma. GLP-1 increased significantly after chemotherapy reaching peak levels at day +7 post-transplant (median (IQR): 8 (4-12) before conditioning vs. 10 (6-17) pmol/L at day +7, P=0.007). The magnitude of the GLP-1 increase was related to the intensity of conditioning. GLP-1 at the day of transplantation (day 0) was positively associated with peak C-reactive protein (CRP) levels (46 mg/L per GLP-1 doubling, P<0.001) and increase in days with fever (32% per GLP-1 doubling, P=0.0058). Patients with GLP-1 above the median at day 0 had higher CRP levels from day +3 to day +10 post-transplant than patients with lower GLP-1 (P≤0.041) with peak values of 238 vs. 129 mg/L, respectively. This study, which represents the first clinical investigation of fasting GLP-1 in relation to high-dose chemotherapy, provides evidence that GLP-1 plays a role in regulation of mucosal defenses. Fasting GLP-1 levels may serve as an early predictor of systemic inflammation and fever in patients receiving high-dose chemotherapy.

U2 - 10.1016/j.bbmt.2019.01.036

DO - 10.1016/j.bbmt.2019.01.036

M3 - Journal article

VL - 25

SP - 1085

EP - 1091

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -

ID: 213358967